• SGI-1027 DNA Methyltransferase Inhibitor Workflows

  2026-08-26

  SGI-1027 combines cofactor-site DNMT inhibition with reported DNMT1 degradation, making it useful for connecting DNA methylation inhibition to gene expression and cancer-cell phenotypes. A gastric cancer study provides a practical framework for pairing RB1/DNMT1 measurements with proliferation, migration, invasion, and tumor-growth assays.

• Lamotrigine: From Ion Channels to Translation

  2026-08-25

  A translational strategy for studying Lamotrigine across neuronal sodium channels, serotonin signaling, cardiac excitability, and CYP19-related endocrine biology while maintaining rigorous assay controls and evidence boundaries.

• Wnt-O-GlcNAcylation Rewires Glycolysis in Bone

  2026-08-25

  The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism that enables Wnt3a-driven osteoblastogenesis. Its central finding is that Wnt stabilizes PDK1 through modification at Ser174, thereby increasing aerobic glycolysis and supporting bone formation and fracture healing.

• Cabozantinib in RCC: From Target Inhibition to Adaptation

  2026-08-24

  Cabozantinib and XL184 are best understood not only as potent multi-kinase inhibitors, but also as tools for studying how renal cell carcinoma rewires signaling under sustained therapeutic pressure. This thought-leadership article connects receptor pharmacology, phosphoproteomic adaptation, motility biology, assay design, and translational decision-making.

• FH1 Small Molecule for iPS Hepatocyte Maturation

  2026-08-23

  FH1 small molecule helps researchers move beyond hepatocyte identity markers by improving albumin secretion, CYP3A4 levels, colony morphology, and AFP profiles in iPS-derived hepatocyte-like cells. This guide translates those findings into a controlled culture workflow, assay strategy, troubleshooting plan, and a cautious bridge to regulated gene-expression research.

• Tolazoline for α2-Adrenergic Receptor Studies

  2026-08-22

  Tolazoline supports concentration-resolved studies of α2-adrenergic receptor signaling, airway smooth muscle responses, and pancreatic islet activity. Its useful differentiation is a dual pharmacology: receptor antagonism at lower experimental concentrations and ATP-sensitive potassium channel effects that become increasingly important at higher concentrations.

• Z-VDVAD-FMK in Apoptosis Pathway Mapping

  2026-08-21

  Z-VDVAD-FMK enables mechanistic separation of caspase-2-associated apoptosis from caspase-1-driven pyroptosis. This article shows how to use the inhibitor in apoptosis assays inspired by new HOXC8–CASP1 findings in lung cancer research.

• T-5224: C-Fos/AP-1 Inhibitor Evidence

  2026-08-21

  T-5224 is a selective C-Fos/AP-1 inhibitor for studying inflammatory transcription, matrix metalloproteinases, cytokines, and osteoclastogenic signaling. Product-dossier evidence supports activity in arthritis-related cellular and mouse models, while a 2024 study links T-5224-induced multiple myeloma cell death to PI3K/AKT-associated ferroptosis.

• T-5224 Induces Ferroptosis in Multiple Myeloma

  2026-08-20

  The 2024 Heliyon study shows that T-5224 kills multiple myeloma cells through ferroptosis linked to suppression of PI3K/AKT signaling, rather than apoptosis alone. Pharmacological rescue experiments and combination testing with bortezomib provide a mechanistic framework for evaluating AP-1 inhibition as a strategy in myeloma research.

• Pazopanib (GW-786034) in ATRX-Defined Glioma Models

  2026-08-20

  Pazopanib (GW-786034) enables pathway-level studies of VEGF signaling, PDGFR activity, angiogenesis inhibition, and tumor cell survival in cancer research. This workflow emphasizes ATRX-stratified glioma assays, controlled DMSO handling, orthogonal readouts, and cautious interpretation of combinations with temozolomide.

• Ertugliflozin and Brain Insulin Signaling in Alzheimer’s

  2026-08-19

  This study tested whether the SGLT2 inhibitor ertugliflozin could reduce Alzheimer-like changes caused by intracerebroventricular streptozotocin, with particular attention to brain insulin signaling and tau hyperphosphorylation. In a rat model, treatment was associated with better cognitive performance, reduced hippocampal tau phosphorylation, and improvements in cholinergic, mitochondrial, apoptotic, and synaptic measures, while the findings remain preclinical and mechanistically associative.

• Tolazoline for α2-Adrenergic Receptor Studies

  2026-08-19

  Tolazoline supports mechanism-focused studies of α2-adrenergic signaling, airway tone, and pancreatic islet function. This guide connects affinity measurements with functional assays while highlighting concentration-dependent channel effects, controls, and troubleshooting decisions.

• N4-Acetylcytidine: RNA Assay Workflows

  2026-08-18

  Use N4-Acetylcytidine as a defined free ac4C nucleoside substrate, analytical reference, or control—not as a guaranteed source of RNA-incorporated modification. This guide translates recent ASCH-domain structural findings into practical enzyme assays, RNA comparisons, sample-preparation controls, and troubleshooting decisions.

• Tobramycin B1856: Reliable Assay Workflows

  2026-08-18

  Tobramycin (SKU B1856) supports controlled microbiology and infection-model workflows where bacterial suppression must be distinguished from mammalian-cell cytotoxicity. This scenario-driven guide links product chemistry, susceptibility-testing evidence, protocol controls, and practical supplier-selection criteria to improve assay interpretation.

• GSDMC Drives Stemness and Immune Evasion in PDAC

  2026-08-17

  A 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a nuclear regulator of pancreatic ductal adenocarcinoma progression rather than only a pyroptosis-associated pore-forming protein. By linking ADAM17-dependent cleavage to stemness, metastasis, and immune evasion, the work suggests that blocking GSDMC processing or nuclear translocation could improve responses to KRASG12D inhibition and PD-1 blockade.

455 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page